University of Southern California
USC Norris Comprehensive Cancer Center


Not logged in...


If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 9L-18-18


A Phase 4, open-label, randomized study of two Inotuzumab Ozogamicin dose levels in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia eligible for hematopoietic stem cell transplantation and who have risk factor(s) for veno-occlusive disease

Type: Treatment
Phase: Phase IV
Status: Open to Accrual
Treatments:
Randomized: Yes
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  George Yaghmour, M.D.
Other Trial Staff:  Simbiso Peresuh, Coordinator, Suraj Chandwani, D.M., Ashot Minasyan, D.M., Christine Duran, Coordinator, Donna Fernando, Coordinator, Nelli Dimitrova, D.M., Hannah Trey, Coordinator, Sonny Tong, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.